HDFN Expert Calls Janssen’s Nipocalimab a Game Changer for Women With the Disease
With encouraging results from its phase 2 trial, Janssen is planning to launch a phase 3 HDFN trial, dubbed AZALEA, later this year.
With encouraging results from its phase 2 trial, Janssen is planning to launch a phase 3 HDFN trial, dubbed AZALEA, later this year.
The American College of Obstetricians and Gynecologists now recommends that all women—ideally before pregnancy—be screened for hemoglobinopathies.